Benchmark Medical/Twist Bioscience pan-cancer methylation products are launched globally

On October 11, 2021, AnchorDx and Twist Bioscience announced that they have jointly developed a methylated library preparation and targeted enrichment NGS sequencing product for pan-cancer species research-Extension Vista-benchmark methylated pan-cancer detection (hereinafter referred to as "methylated pan-cancer detection product") was launched globally on September 24 (US time)
.

This methylated pan-cancer detection product is a technical achievement jointly developed by Benchmark Medical and Twist in the past two years.
It has the advantages of wider coverage, more accurate data analysis, and higher detection efficiency.
It combines the long-term independent accumulation of large samples of benchmark medical The proven advantages of pan-cancer biomarkers, as well as Twist's technical advantages and quality control advantages in probe design, DNA synthesis, can ensure stable and uniform high performance in large-scale screening applications
.

Reference materials:

[1] The pan-cancer methylation product jointly developed by Benchmark Medical and Twist Bioscience is launched globally.